Has Sorina Dancea, MD received payments from drug or device companies?

Yes. Drug and device makers reported $238 in general payments to Sorina Dancea, MD across 12 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sorina Dancea, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sorina Dancea, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sorina Dancea, MD

Rheumatology · Bangor, MENPI 1699975326

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $199 of the $238 with a category attached, or 83.5%. 6 manufacturers reported payments, led by Amgen at 34.9% of the total. Reporting peaked in 2019 at $139 and has fallen 82.5% since, to $24 in 2025. That places this record below the midpoint for rheumatology clinicians in ME, where the typical reported total is $238.

$238in general payments, 2019–2025

Across 12 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$83
Novartis$40
Aurinia Pharma U.S., Inc.$39
E.r. Squibb & Sons, L.L.C.$36
GSK$24
Genentech USA, Inc.$15

What the payments were for

Food & beverage$19983%
Education$3917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	4	$83
Novartis	2	$40
Aurinia Pharma U.S., Inc.	2	$39
E.r. Squibb & Sons, L.L.C.	2	$36
GSK	1	$24
Genentech USA, Inc.	1	$15

How this compares

$238 in reported general payments places this provider in the 50th percentile of 28 rheumatology providers in Maine.

See all rheumatology providers in Maine →

Medicare billing

Part B allowed, 2024

$402,330

Medicare patients

444

Services billed

27,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	149	$1,354,940
Enbrel SureclickEtanercept	146	$1,176,416
Humira(Cf)Adalimumab	28	$269,342
EnbrelEtanercept	31	$258,597
Orencia ClickjectAbatacept	27	$191,960
RinvoqUpadacitinib	12	$85,934
OtezlaApremilast	11	$50,628
Teriparatide	17	$35,277
Hydroxychloroquine Sulfate	1,030	$29,083
MethotrexateMethotrexate Sodium	704	$16,938
Leflunomide	222	$14,662
Celecoxib	135	$5,602
Sulfasalazine DrSulfasalazine	81	$3,817
Diclofenac Sodium	51	$3,746
Duloxetine Hcl	108	$2,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenEnbrel, Otezla	$83	$309,22542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 28 rheumatology providers in Maine.

Other rheumatology in Bangor

Crisostomo BaliogBangor$1K
Courtney CorbeilBangor$538
Sidney BlockBangor$45
Erik OconnellAugusta$27K
Kenneth CalamiaBelfast$11K
Nancy-Nichole BarryBelfast$6K
Samah MusaBrewer$771
Elise McVeighBath$765
Asha ShresthaOrono$622
Diana VradiiBrunswick$543

See the full list for Maine →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →